Vifor Pharma concludes licensing agreement with Zeria to market Veltassa® in japan

PhRMA member companies’ R&D spend reaches record $71.4bn
Credit: Shutterstock.com/ nevodka

Vifor Pharma Group has granted Japanese company Zeria pharmaceutical co., ltd. exclusive rights to develop and commercialise Veltassa® in Japan.

Under the terms of the agreement, Zeria will have the exclusive right to develop Veltassa® for the Japanese market and, once marketing authorisation has been granted, to commercialise it in Japan.

The collaboration with Zeria represents an important step in Vifor Pharma’s promise to make Veltassa® available to patients worldwide. Having Veltassa® and Ferinject® commercialised through the same partner represents a substantive step for Vifor Pharma in its goal towards expanding its cardio-renal network and becoming the global leader in cardio-renal therapies.

“We are very pleased about strengthening our partnership with Zeria and having made a significant step towards making Veltassa® available in Japan, the third-largest pharmaceutical market. We feel extremely fortunate that our trusted partner, Zeria, has chosen to further collaborate with us in offering this novel treatment to hyperkalaemia patients, including those on renin angiotensin aldosterone system inhibitor (RAASi) therapy. RAASi patients benefit in particular because Veltassa®enables them to keep receiving an optimal dose of, and therefore the maximum live-saving benefit from, RAASi treatment,” said Stefan Schulze, President of the Executive Committee and COO of Vifor Pharma Group.